Drug Product Manufacturing
Formulation
The final step for the complete workflow: LNP formulations enable safe and efficient delivery into the cells and lead the way into a new era of genetic medicine. With over 50 cGMP lots generated, we now collaborate with Precision Nanosystem (PNI) expertise to provide critical components for mRNA therapies, further expanding our mRNA manufacturing by adding formulation capabilities to form the most comprehensive portfolio of products and services essential for mRNA vaccines and therapeutics development.
RNA lipid nanoparticle formulations
- Incorporating PNI’s technology and expertise for large scale capacity
- Utilizes PNI’s lipid library, as an initial step for screening
- Leverage PNI’s NanoAssemblr® GMP System to obtain process consistency and encapsulation efficiency
- We optimize and scale based on customer needs through various stages of development and maintaining your desired specifications
Encapsulation
We are also a full service CDMO covering all phases from pre-clinical development to commercial manufacturing for LNP encapsulation. Our integrated mRNA CDMO platform provides manufacture capabilities for final mRNA drug products to advance your therapeutics. Our support through production, analytics, and regulatory will significantly decrease complexity and enhance speed to commercialization to help advance life-enhancing therapeutics.
Fill/Finish
Closed aseptic filling of mRNA drug products that reduces risk and improve agility. Under the Danaher umbrella, Aldevron is positioned to advance multiple candidates, including mRNA vaccines and therapeutics.
Analytical
As important as flexible and scalable platform technologies are to the rapid development of mRNA-based therapeutics, they would not be possible without rapid, robust, accurate, sensitive, and scalable analytical technologies. Aldevron is position with partnership with Danaher Operation Companies, that include PNI, Sciex, and Cytiva, to provide clients the customizable analytical and method assay to validate the process of manufacturing from sequence to vial.
Quality Attribute |
Attribute |
Method |
Identity |
Sequence Confirmation |
RT-Sanger Sequencing |
Identity - UTR |
RT-PCR |
|
Particle Sizing |
DLS |
|
Content |
Concentration – Total RNA |
UV |
Concentration – Unencapsulated RNA |
UV |
|
% Encapsulation Efficiency (%EE) |
%EE = 1 - [Unencapsulated RNA] / [Total RNA] *100% |
|
Concentration – Total Lipid |
Lipid Analysis-UPLC-CAD |
|
Concentration – Individual Lipids |
Lipid Analysis-UPLC-CAD |
|
RNA:Lipid Ratio (N:P ratio) |
Total RNA (if>85% EE)/Total Lipid |
|
Purity |
Capillary gel electrophoresis (CGE) |
Capillary gel electrophoresis (CGE) |
Potency |
Activity Assay |
In vitro Transcription Assay |
Safety |
Endotoxin (Endosafe®) |
USP <85> Kinetic Chromogenic LAL |
Sterility USP<71> |
Sterility USP<71> |
|
Residual Solvent |
UPLC |